ArticleToxicology reports2025
Naringin ameliorates high-fat diet-induced hepatotoxicity and dyslipidemia in experimental rat model via modulation of anti-oxidant enzymes, AMPK and SERBP-1c signaling pathways.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- [Mechanism ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Guang Chenpi Extract as a Multifunctional Phytotherapeutic: Enhanced Effects with Ergothioneine and Polydeoxyribonucleotide on Redox Homeostasis and Tissue Resilience.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Flavonoids in MASLD: preclinical mechanisms, pharmacological targets, and translational challenges.Frontiers in pharmacology · 2026Review
- Dill extract attenuates liver fibrosis and steatohepatitis in obese ratsResearch in pharmaceutical sciences · 2025Article
- Metabolic Reprogramming Through Polyphenol Networks: A Systems Approach to Metabolic Inflammation and Insulin Resistance.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-fat diet causes elevation of steatosis, dyslipidemia and oxidative stress which eventually leads to hepatic injury in the form of non-alcoholic fatty liver disease (NAFLD). Naringin, a natural flavonoid, having tremendous potentiality including antioxidant, anti-inflammatory, hypolipidemic role. Based on this proposition, we investigated the role of naringin in hepatotoxicity and its possible underlying mechanism caused by high-fat diet for prolonged time. Fifteen Wistar rats were divided into three groups: Group A (CON) received normal diet; Group B (HFD) was administered with high-fat diet for 16 weeks; and Group C (THN) was treated with naringin (100 mg/kg B.W.) for last 6 weeks after induction of obesity. After autopsy, various parameters were studied like gravimetry, serum biochemistry, ROS activity, anti-oxidant enzymes, genes expression (AMPK and SREBP-1C), histochemistry, histopathology and ultrastructure of hepatic tissue. In HFD group, Masson's trichome stain intensity increased 6.8-folds, indicating the onset of liver fibrosis; ROS generation and lipid peroxidation (TBARS) were significantly (p < 0.01) increased, whereas SOD and CAT were decreased by 36.7 % and 49.7 %, respectively. Furthermore, these parameters were remained normal in THN group. Besides, HFD group displayed extreme elevation in hepatic SREBP-1C expression (147 %) and downregulation of AMPK gene (77 %) compared to control. The ultrastructural study revealed most important and new insight of this study where HFD induced extreme reticule stress in hepatic tissue which was significantly improved by the treatment of naringin. These findings demonstrate that the naringin may be used as a potential therapeutic agent to combat obesity related hyperlipidemia and NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.